Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10708
Peer-review started: May 9, 2022
First decision: May 30, 2022
Revised: June 10, 2022
Accepted: September 6, 2022
Article in press: September 6, 2022
Published online: October 16, 2022
Processing time: 142 Days and 20.1 Hours
Chondroid syringoma (CS) is a rare tumor of the apocrine or eccrine glands. CS of the lower back is rare, and its clinical manifestations are similar to those of lipoma, which is a common misdiagnosis for this disease.
A 39-year-old woman presented with a 2-year history of an asymptomatic subcutaneous mass on the lower back. The lesions increased progressively over time. The patient denied any history. Dermatological examination showed that there was a subcutaneous mass, ranging from 3-4 cm in diameter, with a clear boundary on the lower back. The surface of the skin was smooth without ulceration or scaling. Histopathologic examination was consistent with the diagnosis of CS.
CS is a rare tumor of the apocrine or eccrine glands. It usually presents as a wellcircumscribed and single subcutaneous masses. Histopathology showed the tumor was located in the dermis, with nests, sheets, and cords of basal-like cells, mucin deposition, and chondroid structures. We herein report a case of CS located in the lower back. CS of the lower back is rare, and its clinical manifestations are similar to those of lipoma, for which it is commonly misdiagnosed.
Core Tip: Chondroid syringoma (CS) is a rare tumor of the apocrine or eccrine glands. It usually occurs in the nose and surrounding areas, and it is rare in the lower back. It usually presents as a well-circumscribed, slow-growing, and single subcutaneous masses. It is easy to clinically misdiagnose CS as lipoma, but histopathological examination is helpful for the diagnosis and treatment of this disease. In our case, combined with the patient’s present illness, dermatological examination, and histopathology, the patient was diagnosed with CS. After surgical resection, no recurrence was found in follow-up visits.
